{
  "claim_id": "claim_004",
  "claim": "Vaccination with a higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
  "document": "Liu_et_al.__2024_",
  "verification_stats": {
    "total_extracted": 7,
    "verified": 5,
    "rejected": 2,
    "verification_rate": 0.7142857142857143
  },
  "verified_evidence": [
    {
      "id": 1,
      "quote": "In year 1, RIV4 induced higher neutralizing and total HA head binding antibodies to cell- A (H3 N2) virus than ccIIV4 and IIV4.",
      "supports_claim": true,
      "explanation": "The quote directly compares the antibody responses induced by the recombinant vaccine (RIV4) to those induced by egg-based standard-dose vaccines (IIV4), showing that RIV4 produced higher neutralizing and total HA head binding antibodies to the A (H3 N2) virus. This directly supports the claim that vaccination with a higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
      "presence_explanation": "The quote 'In year 1, RIV4 induced higher neutralizing and total HA head binding antibodies to cell- A (H3 N2) virus than ccIIV4 and IIV4.' appears in the document on page 1, with only minor formatting differences (e.g., 'cell- A (H3 N2) virus' instead of 'cell-A (H3 N2) virus'). The factual content and meaning are preserved.",
      "support_explanation": "The quote directly compares the antibody responses induced by the recombinant vaccine (RIV4) to those induced by egg-based standard-dose vaccines (IIV4), showing that RIV4 produced higher neutralizing and total HA head binding antibodies to the A (H3 N2) virus. This directly supports the claim that vaccination with a higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
      "original_relevance": "This quote directly compares the antibody responses induced by the recombinant vaccine (RIV4) to those induced by egg-based standard-dose vaccines (IIV4), showing that RIV4 produced higher neutralizing and total HA head binding antibodies to the A (H3 N2) virus, supporting the claim."
    },
    {
      "id": 2,
      "quote": "RIV4 contains 3 times the intended 45 \u00b5g HA/dose/strain compared to IIV4 and ccIIV4 (15 \u00b5g HA/dose/strain). For A (H3 N2), RIV4 vaccination not only improved the quality of the functional neutralizing antibody response, it also significantly increased the quantity of the total A (H3 N2) cell HA head binding antibodies (Fig. 4 A, Fig. S1 A).",
      "supports_claim": true,
      "explanation": "The quote directly supports the claim. It explicitly states that RIV4 (the recombinant vaccine) contains three times the hemagglutinin antigen per dose per strain compared to the standard-dose egg-based vaccines (IIV4 and ccIIV4), and that for A (H3 N2), RIV4 vaccination significantly increased both the quality and quantity of antibody responses. This directly substantiates the claim that higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
      "presence_explanation": "The quote appears on page 9 of the document, though it is split across lines and slightly paraphrased due to formatting. The relevant passage is: 'IIV4 and ccIIV4 (15 \u00b5g HA/dose/strain). For A (H3 N2), RIV4 vaccination not only improved the quality of the functional neutralizing antibody... it also significantly increased the quantity of the total A (H3 N2) cell HA head binding antibodies (Fig. 4 A, Fig. S1 A).' The statement about RIV4 containing 3 times the intended 45 \u00b5g HA/dose/strain compared to IIV4 and ccIIV4 is found earlier on page 2: 'RIV4 contains 3 times the i d 45 HA/d / ...d' (intended 45 \u00b5g HA/dose/strain). The factual content, numbers, and technical details are preserved.",
      "support_explanation": "The quote directly supports the claim. It explicitly states that RIV4 (the recombinant vaccine) contains three times the hemagglutinin antigen per dose per strain compared to the standard-dose egg-based vaccines (IIV4 and ccIIV4), and that for A (H3 N2), RIV4 vaccination significantly increased both the quality and quantity of antibody responses. This directly substantiates the claim that higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
      "original_relevance": "This quote specifies that the recombinant vaccine (RIV4) is a higher-dose vaccine and that it led to a significant increase in both the quality and quantity of antibody responses compared to standard-dose vaccines, directly supporting the claim."
    },
    {
      "id": 3,
      "quote": "In this randomized trial (Clinical trials gov: NCT03722589), sera pre- and post vaccination with quadrivalent inactivated egg based (IIV4), cell culture based (ccIIV4), and recombinant (RIV4) influenza vaccines were compared. RIV4 induced higher neutralizing and total HA head binding antibodies to cell- A (H3 N2) virus than ccIIV4 and IIV4.",
      "supports_claim": true,
      "explanation": "The quote directly supports the claim. It states that in a randomized trial, the recombinant vaccine (RIV4) induced higher neutralizing and total HA head binding antibodies to cell-A (H3N2) virus than both the cell culture-based (ccIIV4) and egg-based (IIV4) vaccines. Since RIV4 is a higher-dose recombinant vaccine and IIV4 is a standard-dose egg-based vaccine, this provides explicit evidence that the higher-dose recombinant vaccine may induce a more robust antibody response than the standard-dose egg-based vaccine, as claimed.",
      "presence_explanation": "The quote is found in the document, though with minor wording differences due to formatting and OCR correction. The relevant passage appears on page 1: 'In this randomized trial (Clinical trials gov: NCT03722589), sera pre- and post vaccination with quadrivalent inactivated egg based (IIV4), cell culture based (ccIIV4), and recombinant (RIV4) influenza vaccines were compared. RIV4 induced higher neutralizing and total HA head binding antibodies to cell- A (H3 N2) virus than ccIIV4 and IIV4.' This matches the quoted content in all essential facts and technical details.",
      "support_explanation": "The quote directly supports the claim. It states that in a randomized trial, the recombinant vaccine (RIV4) induced higher neutralizing and total HA head binding antibodies to cell-A (H3N2) virus than both the cell culture-based (ccIIV4) and egg-based (IIV4) vaccines. Since RIV4 is a higher-dose recombinant vaccine and IIV4 is a standard-dose egg-based vaccine, this provides explicit evidence that the higher-dose recombinant vaccine may induce a more robust antibody response than the standard-dose egg-based vaccine, as claimed.",
      "original_relevance": "This quote describes the design of the study and the finding that RIV4, the higher-dose recombinant vaccine, induced higher antibody responses than the standard-dose egg-based vaccine, providing direct evidence for the claim."
    },
    {
      "id": "comp_1",
      "quote": "In year 2, among the 7 repeat vaccination arms (IIV4-IIV4, IIV4-ccIIV4, IIV4-RIV4, RIV4-ccIIV4, RIV4-RIV4, ccIIV4-ccIIV4 and ccIIV4-RIV4), repeat vaccination with either RIV4 or ccIIV4 further improved antibody responses to circulating viruses compared to repeat vaccination with IIV4.",
      "supports_claim": true,
      "explanation": "The quote directly compares repeat vaccination with RIV4 (recombinant, higher-dose) or ccIIV4 (cell-based) to repeat vaccination with IIV4 (egg-based, standard-dose), stating that RIV4 or ccIIV4 'further improved antibody responses to circulating viruses.' This supports the claim that vaccination with a higher-dose recombinant flu vaccine (RIV4) may induce a more robust antibody response than egg-based standard-dose vaccines (IIV4).",
      "presence_explanation": "The quote appears in the document on page 1 (first paragraph): 'In year 2, among the 7 repeat vaccination arms (IIV4-IIV4, IIV4-ccIIV4, IIV4-RIV4, RIV4-ccIIV4, RIV4-RIV4, ccIIV4-ccIIV4 and ccIIV4-RIV4), repeat vaccination with either RIV4 or ccIIV4 further improved antibody responses to circulating viruses compared to repeat vaccination with IIV4.' The wording is nearly identical to the quote provided, with only minor formatting differences (e.g., 'RIV4-ccIIV4' vs 'RIV4-ccIIV4'). The factual content and meaning are preserved.",
      "support_explanation": "The quote directly compares repeat vaccination with RIV4 (recombinant, higher-dose) or ccIIV4 (cell-based) to repeat vaccination with IIV4 (egg-based, standard-dose), stating that RIV4 or ccIIV4 'further improved antibody responses to circulating viruses.' This supports the claim that vaccination with a higher-dose recombinant flu vaccine (RIV4) may induce a more robust antibody response than egg-based standard-dose vaccines (IIV4).",
      "original_relevance": "This quote shows that repeat vaccination with the recombinant (RIV4) vaccine, which is higher-dose, led to improved antibody responses compared to the standard egg-based vaccine, supporting the claim that higher-dose recombinant vaccines may induce a more robust antibody response."
    },
    {
      "id": "comp_4",
      "quote": "At 6 months post vaccination, waning of HA stalk antibodies were more notable in ccIIV4 and IIV4 groups than in the RIV4 group.",
      "supports_claim": true,
      "explanation": "The quote directly compares the durability of HA stalk antibody responses between the recombinant vaccine (RIV4) and the egg-based standard-dose vaccines (IIV4 and ccIIV4). It states that antibody waning was more notable in the egg-based and cell-based groups than in the recombinant group, indicating that RIV4 induces a more robust and durable antibody response. This directly supports the claim that vaccination with a higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
      "presence_explanation": "The quote 'At 6 months post vaccination, waning of HA stalk antibodies were more notable in ccIIV4 and IIV4 groups than in the RIV4 group.' appears on page 5 of the document. The wording is nearly identical, and the factual content is preserved.",
      "support_explanation": "The quote directly compares the durability of HA stalk antibody responses between the recombinant vaccine (RIV4) and the egg-based standard-dose vaccines (IIV4 and ccIIV4). It states that antibody waning was more notable in the egg-based and cell-based groups than in the recombinant group, indicating that RIV4 induces a more robust and durable antibody response. This directly supports the claim that vaccination with a higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
      "original_relevance": "This quote indicates that the antibody response induced by the higher-dose recombinant vaccine (RIV4) is not only more robust initially but also more durable over time compared to the standard egg-based vaccine."
    }
  ],
  "rejected_evidence": [
    {
      "id": "comp_2",
      "quote": "Comparing pre- and 1 month post vaccination, A (H3 N2) HA stalk binding antibodies were significantly boosted in ccIIV4-RIV4, RIV4-RIV4, IIV4-ccIIV4, and IIV4-RIV4 arms, while A (H1 N1) pdm09 HA stalk binding antibodies were also significantly boosted in ccIIV4-ccIIV4 and RIV4-ccIIV4 arms (Fig. 8 C).",
      "reason": "does not support claim",
      "original_explanation": "This quote demonstrates that vaccination regimens including RIV4 (the higher-dose recombinant vaccine) significantly boosted antibody responses, supporting the claim that RIV4 may induce a more robust antibody response than standard egg-based vaccines."
    },
    {
      "id": "comp_3",
      "quote": "RIV4 contains 3 times the intended 45 \u00b5g HA/dose/strain compared to IIV4 and ccIIV4 (15 \u00b5g HA/dose/strain).",
      "reason": "does not support claim",
      "original_explanation": "This quote provides direct evidence that the recombinant vaccine (RIV4) is a higher-dose formulation compared to the standard egg-based vaccine, which is a necessary condition for the claim about higher-dose vaccines inducing a more robust response."
    }
  ],
  "model_used": "gpt-4.1"
}